Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis

  1. Kim, Y.H.
  2. Prince, H.M.
  3. Whittaker, S.
  4. Horwitz, S.M.
  5. Duvic, M.
  6. Bechter, O.
  7. Sanches, J.A.
  8. Stadler, R.
  9. Scarisbrick, J.
  10. Quaglino, P.
  11. Zinzani, P.L.
  12. Wolter, P.
  13. Eradat, H.
  14. Pinter-Brown, L.C.
  15. Ortiz-Romero, P.L.
  16. Akilov, O.E.
  17. Trotman, J.
  18. Taylor, K.
  19. Weichenthal, M.
  20. Walewski, J.
  21. Fisher, D.
  22. McNeeley, M.
  23. Gru, A.A.
  24. Brown, L.
  25. Palanca-Wessels, M.C.
  26. Lisano, J.
  27. Onsum, M.
  28. Bunn, V.
  29. Little, M.
  30. Trepicchio, W.L.
  31. Dummer, R.
  32. Montrer des auteurs +
Revue:
European Journal of Cancer

ISSN: 1879-0852,  0959-8049

Année de publication: 2021

Volumen: 148

Pages: 411-421

Type: Article

DOI: 10.1016/J.EJCA.2021.01.054 GOOGLE SCHOLAR lock_openAccès ouvert editor

Objectifs de Développement Durable

La source de données: Scopus